Philip Morris International Inc. (PM) Earnings Call Transcript & Summary
April 23, 2024
Earnings Call Speaker Segments
James Bushnell
executiveHello, and thanks for being here. Today we put out a press release with full details about how we performed in the first quarter of 2024. You can find that release on our site, pmi.com. For definitions — including what we mean by smoke-free products, plus adjustments, other calculations, and reconciliations to the closest comparable U.S. GAAP measures for the non-GAAP financial figures mentioned in this presentation — please see Exhibit 99.2 of the company's Form 8-K dated April 23, 2024, and our Investor Relations website. Remarks today include forward-looking statements and projections about future results. Please see the forward-looking and cautionary statements disclosure in today's presentation and press release, which reviews the various factors that could cause actual results to differ materially from projections or forward-looking statements. With me today are Emmanuel Babeau, Chief Financial Officer, and Jennifer Motles, Chief Sustainability Officer. Emmanuel, the floor is yours.
Emmanuel Babeau
executiveThanks, James, and hello everybody. During Q1, we achieved exceptional results that went beyond what we had anticipated, featuring double-digit increases in organic net revenue and operating income, plus currency-neutral adjusted diluted earnings per share, all underpinned by strong volume gains. Our smoke-free segment keeps up remarkable momentum, posting plus 25% organic growth in net revenues alongside plus 38% in gross profit, as IQOS operating leverage and ZYN mix both add favorably. IQOS keeps moving forward quickly, expanding plus 13% in adjusted in-market sales volumes and plus 21% in shipment. IQOS ILUMA drives much of this success and is now offered across 64 markets, accounting for nearly 100% of IQOS volumes beyond Russia. ZYN maintained its substantial expansion in Q1 too, with U.S. volumes climbing plus 80%. Crucially, this revenue achievement converted into solid operating income increases and margin gains, both on an organic basis and in dollar figures. This stemmed especially from rising profitability in our IQOS and ZYN operations, along with better combustible results. We encountered stronger-than-anticipated currency challenges during the quarter, largely because of the Egyptian pound's devaluation. We're implementing countermeasures such as extra pricing and sped-up cost programs, enabling us to achieve Q1 adjusted diluted EPS beyond what we had previously projected in spite of such strains. Although last year's comparable quarter was easy for certain growth metrics, this remarkable beginning to the year positioned us to produce much better-than-anticipated 2024 currency-neutral growth and solid growth in U.S. dollars at current rates. Now for the main figures. Solid shipment volume increase of plus 3.6% drove organic top line growth of plus 11%, or plus 8.6% when currency is included. This shows ongoing superb IQOS and ZYN momentum together with robust combustible pricing. Operating income rose plus 22.2% organically against an easier year-ago quarter, mainly fueled by gross margin gains and slower SG&A growth. Consequently, our organic OI margin widened plus 3.7 percentage points; measured in dollars, adjusted OI rose plus 11.3% while adjusted OI margin widened 90 basis points; we beat our Q1 adjusted EPS guidance thanks to 3 primary reasons: first, the net revenue and profit effect of superior volumes stemming from ZYN's industry-leading results, IQOS HTUs' powerful shipment expansion including some greater-than-anticipated time advantage, and dependable combustible performance. Second, gains from our pricing measures to counter currency challenges; and third, regarding costs, comprising some timing advantage and heightened emphasis on manufacturing and back-office efficiencies to prioritize growth investments. Most of the beat came from underlying business dynamics, which is a promising sign for the rest of the year. In fact, we posted adjusted diluted earnings per share of $1.50, which is plus 23.2% growth when excluding a $0.20 unfavorable currency hit. That figure comprises $0.09 tied to the Egyptian pound's devaluation, which includes a transactional effect of $0.06 mainly stemming from remeasuring foreign currency payable on the balance sheet; now that liquidity in the Egyptian pound has risen, we are lowering our balance sheet exposure, and that process ought to wrap up over the next few weeks. Turning to volumes. At 33.1 billion units, our Q1 HTU shipments came in above our outlook, thanks to solid underlying expansion across geographies plus a larger-than-expected timing effect from shipments into Japan. Roughly 1 billion units made up the incremental trading impact, mostly stemming from Red Sea disruption. Though it remains uncertain, our assumption is that this will return to normal during the second half of the year. As stated earlier, we regard adjusted in-market sales as the finest gauge of underlying HTU growth, since it sits closest to consumer offtake. Adjusted IMS volume posted healthy growth of plus 12.5%, which incorporates the anticipated effect of the characterizing flavor ban in Europe. IQOS momentum remains strong, with outstanding growth in Japan, solid underlying fundamentals in Europe, and an expanding contribution from newer markets, such as Indonesia. For the year, our target remains plus 14% to plus 16% adjusted IMS growth, with roughly plus 10% growth in Q2, then an H2 acceleration fueled by the timing of commercial programs, ILUMA uptake, newer markets and an easier prior year comparison. Total smoke-free volume growth of plus 22% reflects the striking expansion of our oral smoke-free portfolio, driven by ZYN, as pouch equivalent shipment volumes climbed by plus 35.8%. U.S. ZYN shipments rose by plus 80% to 132 million cans. Cigarette achievements slipped by a modest 0.4% in the first quarter, with a notable positive contribution from Turkey as we gained share in a strong overall market. Allow me now to walk through the drivers of our Q1 net revenues. As I noted, volume rose by a remarkable plus 3.6%, including oral. Pricing added plus 5.5 points of growth, mainly from combustible, along with pricing of around plus 3% on HTUs. Smoke-free category mix contributed plus 3.1 percentage points to the top line, mirroring the higher net revenue per unit of IQOS and, to an even greater extent, ZYN. Oral smoke-free product overall lifted our organic net revenue growth by plus 2.2 points, demonstrating its role as a meaningful accelerator. To report a positive contribution from our VEEV e-vapor business, which remained small in the context of the group, delivered good revenue growth; in 2023, there was a negative geographic mix within our combustible business, oral margin market, smoke-free product grew faster and smoke-free product accelerated cigarette declined elsewhere. The positive mix impact of smoke-free product — and pricing are the 3 enduring engines for our transformation and growth. Turning now to the key dynamics of our Q1 profit delivery. Smoke-free gross profit expanded by an impressive plus 38% organically and top line growth of plus 25%. This reflects the very strong performance of U.S. The momentum behind ZYN, along with IQOS scaling up and becoming more efficient to produce, drove this. That solid underlying pickup got an extra boost of just a handful of percentage points from the timing of HTU shipments. We saw a big lift in gross margin across both heat-not-burn and oral nicotine, and an even more remarkable organic jump of 600 basis points for smoke-free as a whole, which accounted for nearly 39% of total gross profit — up 6 percentage points from a year earlier. Organic gross profit growth in combustibles came in notably stronger and beat what we had expected, at 2.3%. Margins also came in above our forecast, which supports a better outlook for the full year. Steady volumes, firm pricing and gains in manufacturing efficiency more than made up for ongoing cost pressure in the category, geographic mix and the effect of IQOS cannibalization. As we noted before, higher costs for leaf, wages and some other inputs rolled into 2024 and ought to moderate in the coming year. We also absorbed roughly $30 million in costs tied to implementing the EU single-use plastic directive, mostly on cigarettes. One standout in Q1 was the strong expansion of operating income margin. Gross margin rose 150 basis points organically and 80 basis points with currency included. That shows great improvement in smoke-free products, their rising share of our business at higher margin, and a better-than-expected trajectory for combustibles. Together with productivity savings, these factors comfortably outweighed the unfavorable technical dilution from third-party manufacturing in Indonesia, which amounted to 30 basis points in the quarter.
Emmanuel Babeau
executiveOn the SG&A side, expenses rose only 1.4% in currency-neutral terms, and that produced 220 basis points of organic margin improvement. Helping drive that result were our programs for allocating and prioritizing resources, including about $160 million of gross cost efficiencies across COGS and SG&A, which keeps us on track toward the $2 billion goal covering 2024 and 2026. Even so, the effect on Q1 margin from how SG&A costs moved, currency factored in, was modest, mostly owing to transactional exposure to the Egyptian pound. For the full year, we still expect SG&A to grow more slowly than the top line; we look for bigger organic SG&A increases across the remainder of 2024, mainly because of how investment spending is phased, which benefited us in Q1. Taken together, these items drove a remarkable 370 basis point increase in organic operating income margin, along with a 90 basis point gain when currency is included. That result exceeded our forecast, so we are raising our outlook for full-year operating income growth, a topic I'll come back to. If we examine adjusted operating income margin from a different angle—by geography—we see widespread worldwide momentum, as each region posted solid organic improvement. When looked at in dollar terms, margin rose across every region except South and Southeast Asia, CIS and Middle East Africa, largely because of the transactional currency effect from the Egyptian pound and technical dilution in Indonesia. Actually, when you take those items out of the picture, the margin expansion in this region was nearly in line with what the group delivered. Now, on to IQOS. Now that ILUMA has rolled out widely, PMI's HTUs continue to strengthen their standing as the number two nicotine brand wherever IQOS is sold. On the earlier basis — which leaves out Indonesia, a market we've added following wider commercialization there — PMI HTUs have just crossed the 10% market share threshold. In 11 markets, our HTUs hold the top spot among nicotine brands, and as we showed at CAGNY, IQOS net revenues have now surpassed Marlboro's. Let's look at IQOS in Europe specifically. HTU share for Q1 climbed by 0.9 points, which also marks the first time the region has gone above 10% share. Although we're at an early stage in plenty of markets, one major catalyst is that ILUMA is becoming more widely available and more widely adopted, and across several markets that used to grow slowly, we're now witnessing a sharp pickup. On a 4-quarter moving average basis, adjusted IMS volumes kept posting solid growth from one quarter to the next and hit an all-time peak of 12.6 billion units. That represents a plus 9.4% increase versus a year earlier in Q1, with outstanding gains in Greece, Portugal, Germany, Spain, U.K. and the Netherlands. In some Central European markets, including Poland and Czech Republic, expansion came at a slower pace, since greater economic strain and sensitivity to price are evident there; in this market, we keep developing our portfolio under the recently launched ILUMA systems to fuel additional growth. If we set aside Ukraine, where adjusted in-market sales didn't grow at all, those sales climbed by a double-digit rate. Just as we expected, the 11 markets that have already been hit by the EU's characterizing flavor ban posted an effect matching our overall regional projection of roughly 2 billion units for the entire year. In line with similar situations we've seen before, the initial response from consumers was to adjust, and afterward their growth rates came back to prior levels. We haven't observed any meaningful shift toward e-vapor products or competing heat-not-burn options, and we expect IQOS's structural growth to keep driving HTU momentum for the balance of the year. Rising offtake shares throughout major cities highlight the strong underlying progress being made in the region. Cities where IQOS adoption is already elevated — Lisbon, Rome, Athens and Budapest — posted very strong gains, showing what further national-level growth could look like. The recent pickup in London, Madrid, Munich and Amsterdam also bodes very well for the IQOS brand in this market and for Europe as a whole; in Japan, the adjusted total tobacco share for our HTU brands rose by an excellent plus 3.1 points, reaching 29.3%. Adjusted IMS volumes were up plus 13%, sustaining the rapid pace of recent quarters. Growth this impressive in a market where category penetration is already high stands as clear proof of IQOS's sustainable growth potential worldwide. Because IQOS enjoys such a solid brand and such a broad commercial presence, we're pursuing expansion through continuous innovation in both devices and consumables. In March, we introduced our latest IQOS device, ILUMA i, into direct channels, and that rollout is still moving across the country. Innovation stays our top priority. When it comes to consumables, our work has delivered a variety of new variants and trial experiences under the premium TEREA brand. The offtake data shown on this chart demonstrates how that has enabled TEREA to keep growing its Japan share, just as mainstream priced SENTIA is doing. Broadening consumer appeal across different price tiers while strengthening and expanding the premium lineup — this successful strategy is a good illustration of how our IQOS business is evolving across markets as the category keeps growing. Tokyo's performance, shared at CAGNY, clearly demonstrates the category's potential: heat-not-burn category volumes overtook combustible in January and have kept rising since. With Japan and Korea leading, the East Asia and Australia region hit almost 2/3 smoke-free net revenue in Q1. Though shipment timing flattered this somewhat, it plainly shows the path forward for the wider company as we pursue our ambition of becoming substantially smoke-free, surpassing 2/3 by 2030. Outside of Japan and Europe, IQOS continues to show strong momentum worldwide—even in lower- and middle-income countries—as key city offtake shares make clear. Indonesia stands out: we've broadened commercialization into selected parts of an additional city, and we've rolled out TEREA clove versions designed to match kretek taste preferences. User numbers have climbed, and we now put the country's IQOS user base at more than 150,000. Our Urban Jakarta city offtake share illustrates this, rising 1.6 percentage points to 3.4% amid an expanding overall industry. We're also pleased to report that, following the launch of ILUMA, IQOS growth has regained pace in South Korea. Based on National c-store offtake data, TEREA has now claimed the number one spot among HTU brands. Over in Seoul, IQOS picked up 1.8 points of market share, landing at 12.8%. Egypt continued to impress — Cairo's offtake share went up 1.3 points to 9.1%, even with the recent pricing moves. We're also encouraged by what we're seeing in Malaysia, Morocco, Lebanon, and the Balkans. Saudi Arabia isn't shown on this slide, but it also had a promising restart, posting a Q1 national offtake share of 1.3% once IQOS commercialization began again in late 2023. And similar to some of our European markets, the November ILUMA launch in Canada has coincided with quicker growth in major cities, as the Toronto example here shows. We're at an early stage with ILUMA, and the rules we have to work within are quite tight, yet all told this marks a favorable development. Now shifting to ZYN, where robust momentum in the United States continued through Q1, delivering sequential growth of more than 70% across rolling 12-month shipments. What stands out even more is that our share of category volume increased for a fourth straight quarter, reaching 74.3% — up 6.9 points or more versus a year ago and 1.3 points or more quarter over quarter, and that came despite a March price hike of $0.15 per ton. Our share of retail value likewise rose, to 79.3%, which highlights both ZYN's premium standing and the strength of its brand equity.
Emmanuel Babeau
executiveThis faster expansion once more signals a significant uplift in store-level sales rates across the country, along with steady broadening of availability, since the category has won considerable appeal among adult nicotine consumers. As we laid out at CAGNY, our priority stays on promoting ZYN in a responsible manner so that unintended usage is avoided. We back the FDA's push to guarantee that nobody under 21 can obtain nicotine products. Swedish Match adheres to a stringent U.S. marketing code, which forbids the use of social media influencers, requires age-gated digital platforms set at 21-plus, and involves working with WeCard so that retail purchases go only to adults of legal age. Let me turn for a moment to combustibles, where our portfolio posted strong organic net revenue growth of plus 3.7% in Q1. That mostly mirrors stronger-than-anticipated pricing of plus 7.9%, with a meaningful lift from Germany and higher pricing in Egypt. Pricing conditions continue to be favorable, and we now project a full year gain of plus 6% to plus 7%, with the annualization impact diminishing in H2. Our cigarette category share rose by plus 0.3 points in Q1, and that figure includes a positive contribution from Algeria, Poland and Turkey, producing only a slight volume decrease for the overall cigarette industry, which was down 0.6%. Our global brands picked up category share in the quarter, with Marlboro adding plus 0.4 points. As previously noted, our 2023 share of segment benefited from a competitor's supply constraints in Egypt, which could normalize this year. As I said before, robust pricing in Q1, together with faster manufacturing productivity, also produced a margin evolution that beat expectations. Now let me give an update on our newest innovation and expansion plans as we push our Smoke-free transformation ahead further. As I discussed earlier, we recently introduced IQOS ILUMA i, our most innovative product so far in Japan. The ILUMA i lineup comprises 3 devices, delivering a variety of adaptable new features. Among these is the new touchscreen on the device order, letting users view relevant information about their experience quickly and easily, plus the pause mode, enabling a user to pause and resume their smoke-free moment right where they stopped. Early consumer response has been highly favorable. Japan became the first market to introduce ILUMA in H2 2021, and we intend to roll out ILUMA i gradually to additional geographies over time. As our Japan and Indonesia performance demonstrates, consumable innovation on the ILUMA platform matters greatly too, as we widen our offering across markets. LEVIA HTUs, which have nicotine but no tobacco leaf, arrived nationwide in the Czech Republic and Romania in Q1, with encouraging initial results. Additional markets are scheduled later this year. DELIA, our new mainstream price brand for HTUs, was introduced in Switzerland, Hungary and Lithuania. In the U.S., we keep getting ready for the first consumer pilot in select cities with the IQOS 3 system. Like I said earlier, we'll start the commercialization with a narrow scope, concentrating on directly activating chosen legal-age nicotine users in a handful of cities, which lets us test various pieces of the commercial model. The core goal behind this consumer activation is to refine how we go about things ahead of the full-scale rollout of IQOS ILUMA, once the FDA gives its authorization. Growing nicotine pouches internationally stays a major priority, especially for ZYN as the number one brand globally; to date we've entered or re-entered 11 markets, with additional ones lined up for later in the year. When it comes to e-vapor, our targeted approach for VEEV is delivering really encouraging initial results. Favorable reactions from consumers are turning into solid repeat purchasing and conversion figures, and we're heading toward profitability in H2. That leads me into what we expect for 2024. Thanks to unmatched momentum in smoke-free volume, top-tier pricing and widening margins, we're lifting our currency-neutral growth projection for the whole year. Along with that strong pricing, a favorable smoke-free mix and cost efficiency also assist us in offsetting currency pressures, and at current rates this ought to let us hit our goal of solid growth when measured in dollars. Because ZYN volumes keep advancing, we're boosting our U.S. shipment estimate to roughly 560 million cans; we've sped up our capacity expansion even more to back this extra increase. Our targets remain strong growth for both adjusted IMS and shipments of IQOS HTUs, plus getting to nearly $15 billion in smoke-free net revenue for 2024 at prevailing exchange rates. Taking into account the higher ZYN shipment projection and a robust pricing view on combustible as well as smoke-free products, we're raising our organic net revenue growth outlook to between plus 7% and plus 8.5%; beyond greater revenue growth, we anticipate faster organic margin expansion; this is largely fueled by a sizable expected jump in our smoke-free gross margin stemming from the IQOS scale effect, ZYN mix and quicker manufacturing productivity gains; it also covers organic gross margin growth in combustible, an area where we'd earlier expected a decline. On top of that, we're aiming to achieve more SG&A efficiency while still putting money into smoke-free growth. Consequently, we're lifting our organic operating income growth projection to between plus 10% and plus 12%. So we're raising our forecast for currency-neutral adjusted diluted EPS growth to between plus 9% and plus 11%; that works out to an adjusted diluted EPS range of $6.19 to $6.31, which factors in an unfavorable currency hit of $0.36 at prevailing rates. The bigger forecast headwind comes mainly from the Egyptian pound's devaluation and the recent softness of the Japanese yen. As I noted, we're acting proactively to lessen the added impact. We anticipate full year growth and operating income margin expansion in organic as well as dollar terms at prevailing exchange rates. That covers organic expansion in both H1 and H2. Following the very good results in Q1, our expectation is a robust first half in total, with organic net revenue and OI growth near the upper portion of the ranges we set for the whole year. Turning to Q2 in particular, we're assuming shipment volume for HTU of between 34 billion and 35 billion, along with ongoing solid volume expansion for ZYN; our projection is currency-neutral adjusted diluted EPS in the range of $1.50 to $1.55, which incorporates unfavorable currency variances of $0.14 at rates currently prevailing. On the balance sheet side, bringing down leverage stays a top priority. Our goal remains a 0.3 to 0.5x gain in the ratio of net debt to adjusted EBITDA during 2024, powered by profit expansion and robust cash flow generation. We likewise keep our target of getting to roughly 2x by the close of 2026 and will look at buybacks as soon as it's confirmed we're on track. Changing topics. Since this quarter lines up with the release of our 2023 integrated report, I'd like to extend a welcome to Jennifer Motles, PMI Chief Sustainability Officer, to give an update regarding our progress on sustainability. Jennifer, the floor is yours. 34 billion to 35 billion.
Jennifer Motles
executiveThank you, Emmanuel. Being part of today's earnings call is genuinely a pleasure. As Emmanuel noted, for our organization sustainability, transformation, and business strategy are not distinct items — they are one and the same. Long-term value creation is where our attention sits, and producing returns for shareholders requires us to succeed at transformation, while succeeding at transformation requires us to succeed at sustainability. What we've reported lately demonstrates that reworking our products generates profitable growth along with value creation across the short, medium, and long term. Even so, transformation likewise means reshaping how our value chain operates and how we interact with society. As we move into new product categories, we work actively with a range of stakeholders and push for regulatory frameworks capable of speeding up industry change and bringing an end to smoking. Business transformation is a journey unique to each company, and sustainability reporting standards and frameworks often don't capture it adequately. To help show our progress toward our smoke-free purpose, we report regularly on our business transformation metric — a tailored set of financial and nonfinancial KPIs. Emmanuel already presented some of these alongside our financial results. Others are visible here. Consider, for example, how a growing portion of commercial and R&D funding is being directed toward smoke-free products—a sign that resources are moving away from our legacy operations and into the effort to substitute cigarettes with improved options. Here's another example: making smoke-free products more widely available and easier to access for adult smokers across the globe stands as 2 key pillars behind that substitution, and with our continued geographic expansion, low and middle income markets now represent 47% of our market presence. You can find these metrics, together with our overall performance for 2023, in our latest integrated report, which came out last month and is posted on our website. That document is comprehensive, addressing our most important sustainability topics, starting with our products. The report points to strides we've made in broadening our smoke-free alternatives, both across product categories and in different regions. It also covers advances on the social and environmental front, which move forward alongside these products to help create lasting value. That includes how we market and sell responsibly, how these products are used, and what we're doing to cut down on waste after consumer use. On top of that, it lays out our headway in bettering the lives of those working within our supply chain, lowering carbon emissions from our operations and value chains, and protecting the natural world. We're also quite happy that our sustainability results and the strength of our reporting keep earning outside recognition. Let me point to a handful of 2023 achievements. PMI made it onto the Dow Jones Sustainability World Index for the very first time, and we were also listed in the DGSI North America for a fourth consecutive year. On top of that, among all U.S. businesses, only PMI earned a AAA rating from CDP. Over 20,000 companies around the globe took part in that rating process, and just 10 came away with this prestigious recognition. One thing worth noting — for investors in certain European markets, and also for ESG or sustainability team funds in the U.S., sector exclusion policies apply to us since we're a tobacco company. Obviously, if you simply leave out particular businesses or industries, that won't fix the root causes behind why they were left out — and for us, that means the damage tied to smoking combustible tobacco. A lot of funds that might drop tobacco because of ESG criteria will keep holding shares in other consumer categories. Even though plenty of those businesses lack harm reduction approaches that can match ours in tackling what their products do. As we move this company beyond combustible products and push toward eliminating smoking across society, we welcome investors' involvement and their pushback to help us speed up this vital transition. Thank you. I'll hand things back to Emmanuel now.
Emmanuel Babeau
executiveThanks, Jennifer. I'll wrap up today's presentation by sharing a few important takeaways. The outstanding momentum we're seeing in IQOS and ZYN volumes, our best-in-class pricing, a favorable category mix, and improved cost efficiency have positioned us to make 2024 a strong year, with faster top line growth and expanding margins. After a remarkable start to the year that exceeded what we had anticipated, we've lifted our forecast for full year growth on a currency-neutral basis. Crucially, we're equally focused on how we perform in dollars. To offset currency headwinds, we're implementing steps such as pricing actions, faster gains in manufacturing productivity, and careful allocation of resources so that growth investment gets prioritized. Our 2024 outlook keeps us squarely on course to hit our 2024 to 2026 CAGR targets. Past 2026, there's even more exciting potential to expand our smoke-free business as we move toward our goal of becoming substantially smoke-free by 2030. Last but not least, our robust growth prospects and the highly cash-generative nature of our business support our capacity to deleverage while staying firmly committed to our progressive dividend policy. We're eager to keep rewarding our shareholders as our transformation brings about sustainable growth. Thanks, and now we're very happy to take your questions.
Matt Smith
analystLooking at Q1, the year got off to a solid beginning. You pointed to improved revenue and margin results that back your decision to lift the guidance for organic revenue as well as constant currency EPS. Broadly speaking, on a constant currency basis, Q1 EPS came in roughly $0.20 above your 1Q guidance, yet you lifted the full year outlook by a bit less than that. Could you discuss any one-off gains in Q1 that might have shifted the timing across the year? Or how do you now see the remainder of the year differently when it comes to the underlying environment or the level of investment?
Emmanuel Babeau
executiveSure, Matt. Glad to walk through why a few of the pieces, though only some of it, obviously, since we began, as I said in my prepared remarks, the year in a very strong manner on an underlying basis. Yet on top of the very strong momentum we are seeing, indeed, there was roughly an extra 1 billion HTU stick related to Red Sea. So that was a benefit in Q1, and we expect it to reverse later in the year for the time being; so that's 1 element that matters. We may have gotten a little help from some combustible volumes, but that's probably more marginal; and given the scale of the combustible business, it's probably smaller; and then the other piece, of course, is the SG&A movement, organically, only a 1.4% increase. We want organic revenue to grow faster than SG&A. But of course, we will have the 10 points of difference that we saw in Q1. So that too will partly reverse over the rest of the year as we bring in some phasing on commercial actions and marketing, advertising later in the year and beginning in Q2, when we will carry more SG&A. So I think with that, you have the main element that added to what was, as I said, a very strong momentum anyway in Q1.
Bonnie Herzog
analystAll right. Emmanuel, I was hoping you could give us a bit more detail on something you mentioned toward the end of your prepared remarks about foreign exchange pressures and the ways you plan to offset them. You pointed to pricing as well as productivity savings, among other things. So if you could elaborate a little more on those levers, assuming you're able to use them, and perhaps explain why you feel more encouraged looking ahead, since these currency challenges keep dragging on and keep affecting your business — I think that would be useful.
Emmanuel Babeau
executiveSure, Bonnie. Glad to walk you through how we see it and what actions we're taking. As we stated at the start of the year, and again at CAGNY, our aim is to produce results measured in dollars. That means that even with yet another sizable ForEx drag — and part of that, I should note, in Q1 we had $0.06 tied to the Egyptian pound, which won't recur next year, so it isn't something that will remain with us; it's essentially a one-time adverse effect — we still intend to generate strong growth over the long run. To achieve that, we have 2 major levers, I'd say. The first concerns price. To be clear, when we discuss price, it's naturally in markets where devaluation has occurred, but not solely there; it's really everywhere — how far can we stretch, how much can we push price increases to their maximum? We believe we're proceeding in a manner that doesn't necessarily put market share at great risk, yet we are clearly, particularly in combustible, pressing ahead with price increases. So that's an action available to us that accounts for a given economic backdrop. In today's conditions, we're doing what we consider optimal and the best we can. Naturally, should there be additional depreciation or devaluation, we would assess whether further steps are possible. Then, regarding productivity and cost efficiency, that involves truly speeding up whatever we can accomplish on productivity, and we're working everywhere. It covers procurement, of course, it covers optimizing the manufacturing teens, it covers logistics. I mean it covers every area where we can unlock additional savings and take advantage of this strong dollar environment. And then there's cost allocation. I mean, naturally, as part of our $2 billion saving program, we continually work on initiatives to be simpler, to create efficiency, to operate more efficiently. So we're doing that, we're trying to speed that up, and here again, we're striving to move faster. Additionally, when it comes to where we put our money, we're focused on the areas delivering the largest, most robust, and — I'd say — most obvious payoff, and that's what lets us drive some gains in profitability that partly counter the unfavorable currency effects. So that covers essentially all of the steps we're taking. We're not claiming we can neutralize whatever direction exchange rates may take; still, I believe our first-quarter results and the guidance for the full year demonstrate that we're able to soften the currency hit to a very considerable degree.
Bonnie Herzog
analystAll right, that's useful. If I could, I'd like to ask a brief question about ZYN. Our contacts in the industry trade are telling us there are some out-of-stocks happening in the U.S. So I was hoping you could give us a bit more detail on that, and on how much volume in the quarter may have been affected. I'm also wondering whether these problems stem from particular production difficulties or instead from demand being so strong, and in the end, when do you think they'll be fixed?
Emmanuel Babeau
executiveThanks, Ben, it's definitely the second one. When a business is expanding at 80%, and ours is expanding at 80%, you can picture that this is definitely putting some strain on the supply chain, no question. Given where things stand now, I'm not certain out of stock is even the right term anymore. What may happen is that at times a particular reference won't be available. At a given moment, not every item in the range will be fully in stock, but if you look at what Nielsen is reporting for Q1 and at our volume, we appear to be expanding quickly, and it's hard to detect any effect stemming from limits on availability. As we've mentioned, we're working extremely hard to get our capacity as high as possible amid this rapidly growing environment for ZYN. Naturally, we're at ease with our ability to supply roughly our 560 million cans. Of course, that isn't the ceiling we're setting when it comes to production capacity. But we're in this stage of adjusting to such strong growth and demand that's rising quickly. So far, I'd say there may be some strain, yet the effect on volumes has been limited.
Owen Bennett
analystAll right, so let's kick off with heated tobacco. Could you expand a little on what the newer markets are bringing in? Is the trend matching what you'd anticipated, or might there be room for upside, since several of the dynamics you mentioned sound quite promising? I'd also welcome any update on bonds and where things stand there, if you can.
Emmanuel Babeau
executiveHappy to, Owen. As you noted, I've been going through quite a few markets where the trajectory for newer markets looks quite compelling. We've discussed Indonesia, and beyond what's already been covered, we could also mention Mexico, where we're seeing a pleasant acceleration and have just introduced ILUMA. The encouraging part is that this isn't resting on just 1 or 2 names — we're building out an expanding roster of newer markets where IQOS is clearly gaining momentum and growing its share, starting as usual in the major cities, since that's where the largest opportunity lies in many of these countries. That said, it's unfolding as we expected. As I mentioned, we anticipate even stronger acceleration during the latter half of the year. We think Taiwan will also begin contributing to this stream of newer markets, so it's tracking with expectations and obviously carries substantial potential, with IQOS quickly being seen in many large cities as an aspirational brand — which is very encouraging for the future and for the brand franchise we can establish there. On top of that, regarding newer markets and how IQOS is performing within them, we do have bonds that we intend to develop going forward. We've been running tests, as we described, in the Philippines and Colombia. We're reviewing the results, making various tweaks, and will present a detailed plan over the next few quarters. We want to ensure the product we bring forward has every element and feature needed for real success, and that's what we're focused on. This will matter greatly across all these markets, because affordability works differently there, so we need a segmented portfolio in which IQOS plays a part — but we also must bring the rest of the bonds portfolio to properly serve that market.
Owen Bennett
analystThat's quite useful. Let me raise 1 additional point. I'd like to dig a little deeper into vape, and what kind of volumes do you believe are achievable in the course of the year. And assuming I understood you correctly, you mentioned profitability would already arrive in H2, which implies volumes are already looking quite strong? And perhaps any thoughts on the markets where you're currently experiencing the greatest momentum?
Emmanuel Babeau
executiveCertainly. Regarding the — naturally, it remains small next to IQOS and ZYN when it comes to its effect at the group level; and our strategy stays the same, meaning we have no desire to be large in vaping if that means losing money. Our aim is to genuinely push forward with VEEV in markets where we're achieving the proper commercial impact, where VEEV is able to make a difference and do so profitably. Truly, volumes got off to a solid start this year. Our expectation is that VEEV will cross into positive bottom line during the second part of the year, and that would be excellent news. We're also putting priority on markets where critical mass exists for us, where the — shall I say, the character of the vaping market is appealing. And right now we're growing quite well, I'd say, in markets including Italy, Czech Republic, France, U.K., while expanding in Canada. Those are markets where we can achieve, so to speak, the size, the mass, and where we possess the impact needed to make our vaping business both successful and profitable.
Faham Baig
analystEmmanuel, thanks for taking questions. I've got a couple too, and both relate to heated tobacco. First, what's your take on any knock-on effects for other European nations following that recent EU court decision regarding Germany's supplementary excise tax? Also, when do you anticipate hearing from the finance court in Düsseldorf? My second question, again about heated tobacco: obviously, pricing has risen over the past few quarters. How do you weigh price against volume growth, and might pricing come in above the initial guidance of low single digits?
Emmanuel Babeau
executiveThanks for asking. Starting with Germany, well, yes, they sought the opinion of the European Court of Justice, but whether their method of applying the extra tax complied with EU law is an issue specific to Germany alone. Therefore, no other nations are affected. It truly is a German matter, stemming from how they put this tax hike into practice. That's the situation. As for the ultimate ruling, since in the end that will come from the German court, I must admit I can't say when we'll have more clarity—presumably within the next few months, of course. But I won't be able to give you anything more precise about when the Düsseldorf court will decide. Several steps remain before they reach that point. So it'll be over the next few months. As things stand right now, I can't tell you the date of their ruling. Turning to your second point about price versus volume: we've stated our position, and I'll maintain it. Indeed, we think we can raise price by more than low single digits, though not to the extent seen in combustible for heat-not-burn. Once more, I believe we're quite clear about the strongly favorable effect of volume expansion in our heat-not-burn operation. Those sales bring in far greater revenue per stick, and they now deliver a better gross margin rate—even considering only the consumable, it stands well above what combustible averages across the group. So the real objective for us is expanding volumes. That's where the logic lies. Beyond that, thanks to IQOS's exceptionally strong franchise and the brand's appeal, we can lift price without risking volume. Still, that's how you ought to view it: for us at present, it's largely about pushing volumes as high as possible.
Gaurav Jain
analystI've got a couple of questions. Let me start with a conceptual angle — picture a place like Tokyo, where heated tobacco now accounts for over half of the category. One could argue that if you pushed premium cigarette prices higher — and they've stayed flat for two years — that would accelerate consumers trading down into IQOS, which in turn would boost IQOS volume growth. It would also lift your dollar EPS growth out of Japan; so why not do something like that in the cities and countries where heated tobacco and IQOS have become the leading form factor?
Emmanuel Babeau
executiveAppreciate that, Gaurav. You know, whenever I discuss anything related to how we price things, I'm going to be very cautious—that shouldn't surprise anyone. So I'd ask you not to look for detailed figures from me. Still, at a conceptual level, it's clear that once we're the leader in this space, and as more people who use nicotine gravitate toward heat-not-burn, there will be opportunities to keep moving upscale and to raise prices further—that's certain. That said, as I said before and explained in response to the earlier question, our view is that at this moment, the priority remains driving volumes as high as possible; that's our focus, naturally, together with strong gross profit per stick and strong contribution. I wouldn't rule out further price increases later on, but I think my stance on where our priorities lie has been pretty clear. That being said, you know that in Japan, raising prices requires approval from the authorities. So this is an area that's regulated at times, which means we don't have all the freedom we might want on this matter. Looking at the long term, it's clear that at present — and we've talked about this before — your IQOS consumables are priced at a discount, even below Marlboro. So that sort of shows you what kind of growth we can probably get to down the road without, I'd say, running into too many problems as time passes — again, it won't occur all at once. Still, like I explained, right now the whole objective is pushing volume as high as possible, and that's bringing with it, I believe, what Q1 demonstrates so clearly: an extremely strong mix effect on how we perform financially.
Gaurav Jain
analystSure. My next question concerns Russia. IQOS volumes there increased, which seems odd since you've stopped putting money into iQOS in that country. So to begin with, could you remind us what Russia contributes to your EPS? And what should we expect for Russia IQOS shipments this year?
Emmanuel Babeau
executiveLook, regarding Russia, one needs a degree of caution about the shipments you observe. Those don't always completely mirror consumer offtake, since some movement can come from neighboring countries. So I'd say caution is warranted. Russia is a market that hasn't been — looking back, I noted that 1 quarter lets us draw any conclusion. From the start of the war in Ukraine, Russia has unfortunately been a market displaying no sort of significant growth. At present, nothing gives us cause to think Russia will all at once turn into a growth market, since fundamentally nothing has shifted; and that country has of course been affected by currency depreciation, which has been weighing on its share of EPS. So I believe we had mentioned 7% to 8%. I think a revision will be needed. I don't have the figure for '24 on the outlook at the top of my mind. But it was that sort of level — roughly 9%, 10% — and I think because of currency, it has been shedding some weight in the company's overall performance.
Callum Elliott
analystSo I'd like to build on what Bonnie asked regarding growth in dollar terms. Back in 2013, Emmanuel, I believe your dollar EPS stood at $5.40 per share. That means you've compounded dollar EPS growth of roughly 1.5% across the next 10, 11 years. So you've had best-in-class organic growth paired with what is likely worst-in-class dollar EPS growth across that 10-year stretch, which is genuinely striking, because those 10 years contain the entire build-out of this IQOS business, which has been quite extraordinary. So my question is this: you clearly laid out a number of initiatives when answering Bonnie about how you intend to drive dollar growth. Maybe you could go back to those factors and ask which ones are actually fresh — ones that didn't exist during that nearly decade-long period, which may have been providing support throughout those previous 10 years. What stood out to me in those factors was that it seemed like items such as pricing and so on. All of those have been around for the last 10 years and haven't enabled you to counteract the FX. So can you offer anything that's new which would give investors confidence that, should FX headwinds persist, you're able to generate dollar growth for your business?
Emmanuel Babeau
executiveThanks for your question. Well, to begin with, I suppose you're working from the assumption that the ForEx headwind will continue in the years ahead, which I think nobody can truly predict. We know currency can go through cycles, and it's true that the last 10 years have involved a strengthening dollar. We've seen other cycles where the dollar was weakening more against at least other hard currency. So nobody knows what will happen. I think what we're saying — and thank you for giving me a reason to perhaps repeat and clarify this — is that we are today in a position to put together very strong growth before ForEx. Looking at our '24 guidance, I think what you can see is that we're still delivering a highly dynamic top line, while operating income growth is really picking up speed. For 2024, our target is now double-digit growth before currency impact. Beyond that, we intend to take pricing action, and the environment as we see it today supports that. Of course, there's the fact that combustible pricing is something we can now deploy very tactically. We recognize that CCs aren't where our future lies. That means we have the ability to use pricing tactically to drive better performance. In addition, we're raising prices at the HTU level. There's also been a bit of a price bump for ZYN. So when we look at the pricing landscape worldwide, it strikes us as promising going forward. Turning to costs: it's true that across the last few years we directed a substantial amount of money into investments, and each time we made a spending move anywhere in the company — whether that involved innovation, science, R&D, or manufacturing — we told you about it. Right now, as you'd expect, our smoke-free product has reached critical mass, and a number of the things we're working on could be done more efficiently. Quite a few activities that we have been gaining knowledge from and that we will put into practice as our journey continues, so all of this, in our view, is likewise handing us strong ammunition and the ability to produce efficiency at a really elevated level going forward. So that's everything — and they matter a great deal, they are quite plentiful, every lever we possess to achieve results in dollar terms down the road.
Callum Elliott
analystThat's useful. Perhaps I could pose one more question. A bunch of American consumer staples businesses are putting out results today, and a lot of them ran into comparable FX challenges — you know, extra FX pressure during the last 2 or 3 months, just like PMI. What stands out to me is that among several of those firms, even a plain-vanilla U.S. toilet paper maker has, this quarter, been more successful at countering these added emerging market FX pressures by, say, quickly rolling out extra price hikes to counter them. So I suppose what I'm asking is whether something about the business's structure leaves it less nimble when reacting to such FX shifts compared with some of your other consumer staples competitors beyond tobacco.
Emmanuel Babeau
executiveWell, may I respond that what you're asking is quite speculative, since you want me to draw comparisons with other businesses that clearly differ a great deal in, I'd say, how they allocate capital, their perspective, what they need to accomplish. What we're creating here is a business with enormous growth prospects. So naturally we won't restrict any of the initiatives, any of the spending we need to make to continue expanding the business and capture the complete opportunity available through our smoke-free portfolio. Perhaps that contrasts with the paper operation you brought up. Honestly, I have no idea, because I'm not aware of what you mean or that particular circumstance. Still, I believe it's tough to likely compare companies dealing with different — possibly different paths. That's what I'd say.
James Bushnell
executiveWe appreciate everyone being with us. That wraps up today’s call. Should you have any additional questions, feel free to reach out to the Investor Relations team. Thanks once more, and enjoy the rest of your day.
Emmanuel Babeau
executiveBye-bye. Speak to you soon.
Operator
operatorThis concludes today's conference call. Thank you for participating. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.